Free Trial
NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

Arcturus Therapeutics logo
$14.79 +0.99 (+7.17%)
Closing price 04:00 PM Eastern
Extended Trading
$14.84 +0.06 (+0.37%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

Key Stats

Today's Range
$13.92
$15.20
50-Day Range
$10.84
$14.79
52-Week Range
$8.04
$25.88
Volume
837,490 shs
Average Volume
419,709 shs
Market Capitalization
$401.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.00
Consensus Rating
Buy

Company Overview

Arcturus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

ARCT MarketRank™: 

Arcturus Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 268th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arcturus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arcturus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.22) to ($0.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcturus Therapeutics is -5.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcturus Therapeutics is -5.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcturus Therapeutics has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Arcturus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    20.02% of the float of Arcturus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcturus Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arcturus Therapeutics has recently decreased by 9.64%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Arcturus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Arcturus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.02% of the float of Arcturus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcturus Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arcturus Therapeutics has recently decreased by 9.64%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Arcturus Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.60% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arcturus Therapeutics' insider trading history.
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARCT Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

ARCT Stock Analysis - Frequently Asked Questions

Arcturus Therapeutics' stock was trading at $16.97 on January 1st, 2025. Since then, ARCT stock has decreased by 12.8% and is now trading at $14.79.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its earnings results on Monday, May, 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($1.58) by $1.06. The biotechnology company had revenue of $29.38 million for the quarter, compared to the consensus estimate of $25.64 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 27.41% and a negative net margin of 47.47%.
Read the conference call transcript
.

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/12/2025
Today
7/09/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARCT
CIK
1410997
Fax
N/A
Employees
180
Year Founded
N/A

Price Target and Rating

High Price Target
$70.00
Low Price Target
$35.00
Potential Upside/Downside
+270.2%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$80.94 million
Pretax Margin
-47.72%

Debt

Sales & Book Value

Annual Sales
$152.31 million
Price / Cash Flow
N/A
Book Value
$8.90 per share
Price / Book
1.64

Miscellaneous

Free Float
22,971,000
Market Cap
$395.57 million
Optionable
Optionable
Beta
2.27

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ARCT) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners